Press release |

People Living with HIV/AIDS: India must not sacrifice us in trade agreement with Europe

New Delhi, 12 March 2010 — As the final round of closed-door negotiations for a Free Trade Agreement (FTA) between India and the European Union (EU) is about to start this month, people living with HIV/AIDS are protesting to ensure Indian negotiators do not give in to pressure to accept terms that will seriously hamper access to medicines for millions of people living in the developing world.

“We are marching to call on the Indian government not to trade away our lives,” said Loon Gangte, president of the Delhi Network of Positive People (DNP+).  “Lifelong treatment for people living with HIV depends on continued access to newer AIDS medicines. Because of international trade rules that India has already signed in the past, some of our newer AIDS medicines are already patented and this makes them completely unaffordable.  We want to know on behalf of whom is our government negotiating?”  

In 2005, in order to comply with the international trade rules, India was obliged to grant patents on medicines, but the country also introduced measures to protect public health and limit abusive patenting.  But the bilateral trade agreement negotiated with the EU now threatens to impose even higher standards of intellectual property protection, enabling companies to maintain prohibitively high prices on medicines

“As the source of 92 percent of the AIDS medicines used in developing countries today, India is the pharmacy of the developing world.  So the impact of this also stretches far beyond India,” said Médecins Sans Frontières Campaigner Leena Menghaney.  “In recent free trade agreements  signed with the EU or the US, developing countries agreed to introduce very strict intellectual property rules that drastically restrict ability to produce or trade in affordable generic medicines.  If India also gives in, access to treatment for people living with HIV/AIDS and other patients will have been sacrificed in the negotiation process.”

Specific measures that Europe is pushing like data exclusivity, which delays the registration of generic medicines, and an extension of the patent term beyond 20 years, are unnecessary under international rules.  In addition, after multiple incidents of seizing Indian generic medicines in transit to other developing countries in Latin America, and Africa, the EU is now seeking to legitimise such measures by forcing India to adopt them in the FTA.

“This FTA is the latest step in a long attack by the US and the EU to shut down India’s generic industry,” said Dr. Amit Sen Gupta, of Jan Swasthya Abhiyan.  “Previously the US and EU strategy was to force India, the biggest source of generic medicines, to grant patents on medicines.  India agreed to do this when it signed up to the TRIPS Agreement and this has had a serious impact on the accessibility of newer medicines. Now with this FTA the EU is trying to force India to adopt ever-higher standards of intellectual property. India has both a moral duty and a legal right to say no.”

Neither the Indian Parliament nor affected communities including people living with HIV have been given the opportunity to be heard on the progress of the negotiations.

“Before the negotiations are concluded, there is an urgent need that Parliament has an opportunity to debate and review critically the terms of the free trade agreement,” said Venkatesh Nayak, working committee member of the National Campaign for People's Right to Information.

Informal talks between European and Indian negotiators are reportedly opening in New Delhi this week, before formal talks take place in Brussels in April. The EU says it wants to conclude the FTA negotiations ahead of the EU-India summit scheduled for October 2010.